How the brand begins to be positioned across the spectrum of medical communications — specifically how the science behind the brand and trial results begin to be discussed at global and local congresses, from interactive and traditional exhibit stands to symposia, from posters to special social events — starts in earnest during Phase III trials, according to Mario Nacinovich Jr., managing director of Axon. With solid Phase III data, public relations efforts can bolster momentum as the brand begins to place great importance on bridging the gap between corporate and stakeholder interests, whether that involves patient advocacy, professional communications, or government… Experts on this topic Mario Nacinovich Jr., Managing Director of Axon Robin Winter-Sperry, M.D., President and CEO of Scientific Advantage and Science Oriented Solutions (SOS) Nagaraja Srivatsan, VP and Head of Life Sciences, North America, Cognizant Stuart Young, Executive VP, Clinical Monitoring, at Chiltern Martha Feller, Ph.D., Global Executive VP, Operations, at i3 Research John Benbrook, CEO of MMG Dave Evans, Chief Information Officer at Octagon Research Solutions
